Personalized, adaptive deep brain stimulation (DBS) can enhance the control of motor symptoms of Parkinson's disease (PD) compared with standard DBS, new research suggests. In a blinded randomized ...

The US Food and Drug Administration (FDA) has approved the first adaptive deep brain stimulation (aDBS) system for Parkinson’s disease (PD) that self-adjusts therapy to individual brain activity in ...

Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adaptive ...

This video is no longer available. Rick Schena, of Alexandria, Virginia, and his doctor at MedStar Health, in McLean, have begun using the latest technology — adaptive deep brain stimulation — in his ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...